Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

SIV can be entrenched in tissues before virus is detectable in blood plasma

SIV can be entrenched in tissues before virus is detectable in blood plasma

Scientists have generally believed that HIV and its monkey equivalent, SIV, gain a permanent foothold in the body very early after infection, making it difficult to completely eliminate the virus even after antiretroviral therapy has controlled it. [More]
EGPAF experts to deliver presentations at AIDS 2014

EGPAF experts to deliver presentations at AIDS 2014

Experts from the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) will give oral presentations, moderate conference events, and exhibit a variety of educational posters and abstracts related to ending AIDS in children. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
HIV self-testing increases proportion of adults initiating antiretroviral therapy

HIV self-testing increases proportion of adults initiating antiretroviral therapy

Among adults in the African country of Malawi offered HIV self-testing, optional home initiation of care compared with standard HIV care resulted in a significant increase in the proportion of adults initiating antiretroviral therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation. [More]

Annual HIV diagnosis rate in the U.S. decreases more than 30%: Study

The annual HIV diagnosis rate in the U.S. decreased more than 30 percent from 2002-2011, with declines observed in several key populations, although increases were found among certain age groups of men who have sex with men, especially young men, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Discovery presents new challenges for HIV eradication efforts

Discovery presents new challenges for HIV eradication efforts

The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART). [More]
Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]

MPP announces 7 new sub-licensing agreements for manufacture of generic HIV medicines

MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure [More]
New software-based method identifies patients with newly diagnosed HIV using EMRs

New software-based method identifies patients with newly diagnosed HIV using EMRs

A new, validated software-based method for identifying patients with newly diagnosed HIV using electronic medical records (EMRs) is described in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. [More]
Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan enters into definitive agreement to acquire Abbott's branded generics pharmaceuticals business

Mylan Inc. today announced that it has entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business ("the Assets") in an all-stock transaction. [More]
"Expressive therapy" intervention helps HIV women, improves social support

"Expressive therapy" intervention helps HIV women, improves social support

New research from UC San Francisco shows that an "expressive therapy" group intervention conducted by The Medea Project helps women living with HIV disclose their health status and improves their social support, self-efficacy and the safety and quality of their relationships. [More]
HIV detected in Mississippi baby after apparent cure

HIV detected in Mississippi baby after apparent cure

In November 2013, it was reported that an infant (known as the “Mississippi baby”) had been in prolonged remission from HIV and was apparently cured. However, after 2 years without taking antiretroviral therapy and having no evidence of the virus, the child now has detectable levels of HIV. [More]
Mississippi baby: Infant seemingly cured of HIV has detectable levels of HIV

Mississippi baby: Infant seemingly cured of HIV has detectable levels of HIV

The child known as the "Mississippi baby"-an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall-now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case. [More]

Failure to provide adequate HIV services threatens global progress on HIV response, warns WHO

Failure to provide adequate HIV services for key groups - men who have sex with men, people in prison, people who inject drugs, sex workers and transgender people - threatens global progress on the HIV response, warns WHO. [More]
Mylan launches Telmisartan Tablets USP

Mylan launches Telmisartan Tablets USP

Mylan Inc. today announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis® Tablets. [More]
New meta-analysis highlights significant gaps in hepatitis C care

New meta-analysis highlights significant gaps in hepatitis C care

A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs. [More]
HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology. [More]